Form 8-K

8-K — Cytek Biosciences, Inc.

Accession: 0001193125-26-335212

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001831915

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d118986d8k.htm (Primary)

EX-99.1 (d118986dex991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d118986d8k.htm · Sequence: 1

8-K

false 0001831915 0001831915 2026-08-05 2026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 5, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40632

47-2547526

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

47215 Lakeview Boulevard

Fremont, California

94538

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

CTKB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On August 5, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description of Exhibit

99.1

Press release dated August 5, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytek Biosciences, Inc.

Date: August 5, 2026

By:

/s/ Wenbin Jiang

Wenbin Jiang, Ph.D.

President and Chief Executive Officer

EX-99.1

Filename: d118986dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Cytek Biosciences Reports Second Quarter 2026 Financial Results

FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or

“Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026.

Recent Highlights

•

Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the

second quarter of 2025

•

Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panels

•

Introduced Cytek Aurora™ Evo instrument configurations

with expanded automation capabilities for highly automated lab environments

•

Total recurring revenue, comprised of service and reagent revenues, reached $18.5 million in the second

quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 32% on a trailing-12-month basis as of the second quarter of 2025

•

Expanded to a total installed base of 3,933 Cytek instruments, adding 142 units in the second quarter of 2026

•

Updates full year 2026 total revenue guidance to $207 million to $212 million, raising the midpoint by

$1 million

“Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong

double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating

adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the

remainder of 2026 and the long-term opportunity ahead.”

Second Quarter 2026 Financial Results

Total revenue for the second quarter of 2026 was $48.1 million, a 6% increase compared to the second quarter of 2025. The increase in revenue was driven

by strong instrument growth in the U.S. and in China, and continued growth in service.

GAAP gross profit was $28.3 million for the second quarter of

2026, a 19% increase compared to the second quarter of 2025. GAAP gross profit margin was 59% in the second quarter of 2026 compared to 52% in the second quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation

expense and amortization of acquisition-related intangibles, was 61% in the second quarter of 2026 compared to 56% in the second quarter of 2025. Excluding the impact of a one-time tariff refund, GAAP and

adjusted gross margin in the second quarter of 2026 were 53% and 56%, respectively.

Operating expenses were $39.7 million for the second quarter of 2026, a 15% increase compared to the

second quarter of 2025 due to increased research and development, sales and marketing, and general and administrative expenses.

Research and development

expenses were $9.7 million for the second quarter of 2026, a 10% increase compared to the second quarter of 2025.

Sales and marketing expenses were

$13.2 million for the second quarter of 2026, a 9% increase compared to the second quarter of 2025.

General and administrative expenses were

$16.8 million for the second quarter of 2026, a 24% increase compared to the second quarter of 2025 due to litigation-related expenses, severance and personnel costs.

Loss from operations in the second quarter of 2026 was $11.4 million compared to loss from operations of $10.6 million in the second quarter of

2025. Net loss in the second quarter of 2026 was $12.2 million compared to a net loss of $5.6 million in the second quarter of 2025.

Adjusted

EBITDA loss in the second quarter of 2026 was $1.5 million compared to positive adjusted EBITDA of $1.3 million in the second quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and a write-off of an investment in an early-stage technology company.

Cash, cash equivalents and marketable securities

totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026, a decrease of $0.2 million.

2026

Outlook

Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising

the midpoint by $1 million, assuming no change in current foreign currency exchange rates.

Webcast Information

Cytek will host a conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m.

Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering

high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology.

Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments,

the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the

Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions

for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than

Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks

of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and

webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry

conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure

requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of Non-GAAP Financial Information

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”)

and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including

“Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial

measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors.

Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP.

Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its

business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of

forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,”

“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or

similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities,

product plans and expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; and Cytek’s future

financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to

management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or

achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is

not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions;

Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future

performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source

suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key

employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets;

Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance

its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk

Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, Cytek’s Quarterly Report on Form 10-Q

to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by

Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee

that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on

which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based,

except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed

through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

Media Contact:

Stephanie Olsen

Lages & Associates

(949)

453-8080

stephanie@lages.com

Investor Contact:

Mark Meehan

Cytek Biosciences

mmeehan@cytekbio.com

Cytek Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

June 30,

2026

December 31,

2025

Assets

Current assets:

Cash and cash equivalents

73,846

90,853

Marketable securities

188,158

170,676

Trade accounts receivable, net

49,698

62,509

Inventories

52,251

48,428

Prepaid expenses and other current assets

13,978

19,530

Total current assets

377,931

391,996

Property and equipment, net

20,801

18,009

Operating lease

right-of-use assets

10,962

11,315

Goodwill

16,690

16,697

Intangible assets, net

14,865

16,821

Other noncurrent assets

5,685

6,704

Total assets

446,934

461,542

Liabilities and stockholders’ equity

Current liabilities:

Trade accounts payable

8,408

6,410

Legal settlement liability, current

2,353

2,495

Accrued expenses

23,855

23,417

Other current liabilities

20,513

16,978

Deferred revenue, current

29,206

28,504

Total current liabilities

84,335

77,804

Legal settlement liability, noncurrent

6,368

6,786

Deferred revenue, noncurrent

18,058

18,339

Operating lease liability, noncurrent

13,517

14,042

Long-term debt

246

525

Other noncurrent liabilities

2,456

2,307

Total liabilities

124,980

119,803

Stockholders’ equity:

Common stock, $0.001 par value; 1,000,000,000 authorized shares as of June 30, 2026 and

December 31, 2025, respectively; 129,982,753 and 128,550,136 issued and outstanding shares as of June 30, 2026 and December 31, 2025, respectively

130

129

Additional paid-in capital

451,846

441,107

Accumulated deficit

(132,761

)

(101,738

)

Accumulated other comprehensive income

2,739

2,241

Total stockholders’ equity

321,954

341,739

Total liabilities and stockholders’ equity

446,934

461,542

Cytek Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Three months ended June 30,

Six months ended June 30,

(In thousands, except share and per share data)

2026

2025

2026

2025

Revenue, net:

Product

32,556

31,415

61,335

59,525

Service

15,584

14,187

30,940

27,534

Total revenue, net

48,140

45,602

92,275

87,059

Cost of sales:

Product

12,884

14,921

28,805

30,450

Service

6,916

6,814

13,876

12,585

Total cost of sales

19,800

21,735

42,681

43,035

Gross profit

28,340

23,867

49,594

44,024

Operating expenses:

Research and development

9,741

8,826

19,345

18,550

Sales and marketing

13,174

12,134

24,820

24,643

General and administrative

16,825

13,531

35,292

26,429

Total operating expenses

39,740

34,491

79,457

69,622

Loss from operations

(11,400

)

(10,624

)

(29,863

)

(25,598

)

Other income (expense):

Interest expense

(281

)

(414

)

(543

)

(705

)

Interest income

819

555

1,606

1,063

Other income (expense), net

(781

)

3,708

(216

)

7,199

Total other income (expense), net

(243

)

3,849

847

7,557

Loss before income taxes

(11,643

)

(6,775

)

(29,016

)

(18,041

)

Provision for (benefit from) income taxes

515

(1,192

)

2,008

(1,056

)

Net loss

(12,158

)

(5,583

)

(31,024

)

(16,985

)

Net loss, basic and diluted

(12,158

)

(5,583

)

(31,024

)

(16,985

)

Net loss per share, basic

(0.09

)

(0.04

)

(0.24

)

(0.13

)

Net loss per share, diluted

(0.09

)

(0.04

)

(0.24

)

(0.13

)

Weighted-average shares used in calculating net loss per share, basic

129,460,518

126,934,294

129,084,814

127,632,999

Weighted-average shares used in calculating net loss per share, diluted

129,460,518

126,934,294

129,084,814

127,632,999

Comprehensive loss:

Net loss

(12,158

)

(5,583

)

(31,024

)

(16,985

)

Foreign currency translation adjustment, net of tax

517

603

845

Unrealized loss on marketable securities

(147

)

(33

)

(348

)

(98

)

Net comprehensive loss

(11,788

)

(5,013

)

(30,527

)

(17,040

)

Cytek Biosciences, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(Unaudited)

Three Months Ended

Six Months Ended

(In thousands)

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2025

GAAP gross profit

28,340

23,867

49,594

44,024

Stock based compensation

736

1,110

1,465

2,196

Amortization of acquisition-related intangible assets

490

481

984

974

Non-GAAP adjusted gross profit

29,566

25,458

52,043

47,194

GAAP gross margin

Non-GAAP adjusted gross margin

GAAP net income

(12,158

)

(5,583

)

(31,024

)

(16,985

)

Depreciation and amortization

2,985

2,988

5,797

5,869

Provision for (benefit from) income taxes

515

(1,192

)

2,008

(1,056

)

Interest income

(819

)

(555

)

(1,606

)

(1,062

)

Interest expense

281

414

543

705

Foreign currency exchange loss (gain)

729

(1,593

)

1,881

(2,871

)

Stock based compensation

5,339

6,791

10,200

13,420

Write-off Investment

1,587

—

1,587

—

Non-GAAP adjusted EBITDA

(1,541

)

1,270

(10,614

)

(1,980

)

Investment income

(1,383

)

(2,048

)

(3,012

)

(4,309

)

Non-GAAP adjusted EBITDA excluding investment

income

(2,924

)

(778

)

(13,626

)

(6,289

)

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Aug. 05, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001831915

Document Type

8-K

Document Period End Date

Aug. 05, 2026

Entity Registrant Name

Cytek Biosciences, Inc.

Entity Incorporation State Country Code

Entity File Number

001-40632

Entity Tax Identification Number

47-2547526

Entity Address, Address Line One

47215 Lakeview Boulevard

Entity Address, City or Town

Fremont

Entity Address, State or Province

Entity Address, Postal Zip Code

94538

City Area Code

(877)

Local Phone Number

922-9835

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, par value $0.001 per share

Trading Symbol

CTKB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration